Persistent hypertriglyceridemia in statin-treated patients with type 2 diabetes mellitus

Figures & data

Table 1 Proportion of patients with type 2 diabetes mellitus who attained the European Society of Cardiology treatment targets while not receiving any lipid-lowering treatment*

Lipid parameter	Number, n/N	% of total population
TC < 4 mmol/L	599/2750	21.2
LDL-C < 2.0 mmol/L	473/2459	19.2
HDL-C > 1.0 mmol/L (male)	900/1458	61.7
HDL-C > 1.2 mmol/L (female)	727/1307	55.6
Fasting TG < 1.7 mmol/L	1539/2667	57.7

Note:

* Any lipid-lowering treatment includes statins, fibrates, nicotinic acids, and polyunsaturated fatty acids either as monotherapy or in combination.

Abbreviations: HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol.

Table 2 Proportion of patients with type 2 diabetes mellitus who received statin monotherapy and attained the European Society of Cardiology triglycerides (TG) targets while receiving statin monotherapy

Statin	Number of patients receiving statin monotherapy (N = 12,419)	% of the total number of patients receiving statin monotherapy treated with each statin	Number of patients treated with statin monotherapy and had TG level recorded	% of patients treated with statin monotherapy and had TG level recorded who attained TG target (<1.7 mmol/L)
Simvastatin	6707	69.5	6351	56.1
Atorvastatin	2154	22.3	2063	48.3
Rosuvastatin	428	4.4	409	42.8
Pravastatin	316	3.3	297	52.5
Fluvastatin	42	0.4	41	56.1

Table 3 Proportion of patients with type 2 diabetes mellitus who attained the European Society of Cardiology treatment targets while receiving statin monotherapy

Lipid parameter	Number, n/N	% of those using statin
TC < 4 mmol/L	4284/9052	47.3
LDL-C < 2.0 mmol/L	3445/8201	42.0
HDL-C > 1.0 mmol/L (male)	3096/5307	58.3
HDL-C > 1.2 mmol/L (female)	2252/4132	54.5
Fasting TG < 1.7 mmol/L	4916/9161	53.7

Abbreviations: HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides.

Table 4 Proportion of patients with type 2 diabetes mellitus who received statin monotherapy, stratified by dose

Statin	Dose, mg	Number of patients receiving each dose	% of patients receiving the dose of each statin
Atorvastatin	10	532	24.7
	20	709	32.9
	40	746	34.6
	80	167	7.8
Fluvastatin	20	13	31.0
	40	25	59.5
	80	4	9.5
Pravastatin	10	72	22.8
	20	89	28.2
	40	155	49.1
Rosuvastatin	5	57	13.3
	10	252	58.9
	20	104	24.3
	40	15	3.5
Simvastatin	10	423	6.3
	20	1935*	28.9
	40	4267	63.6
	80	82	1.2

Note:

* Includes one patient taking 20 mg/mL liquid suspension.